Tyrosine Kinase Inhibitor Markets – Oncology


One promising area is a class of drugs known as tyrosine kinase inhibitors, which  phosphorylate specific amino acids on substrate enzymes, changes that subsequently alter signal transduction leading to downstream changes in cellular biology. This report examines tyrosine kinase inhibitor markets oncology and the three dozen therapeutic drugs that currently define the market. Visit https://www.greystoneassociates.org/oncology-tyrosine-kinase-inhibitors/ for more information.



Traditional cancer therapy has focused on removal or destruction of tumors cells by surgery, radiation and rather non-selective types of chemotherapy. Surgery and radiation are often effective with tumors which are localized and have not metastasized to multiple sites throughout the body. Intensive research and clinical trial activity have led to a number of targeted treatments, using novel pathways and signaling, that have achieved results representing a new era in oncology and antineoplastic therapeutics. These approaches have attracted a growing number of drug developers to tyrosine kinase inhibitor markets, anxious to profit from therapies that can ease the physical, psychological and emotional burden of cancer. Tyrosine kinase inhibitor markets provides comprehensive assessments of a treatment segment that is changing cancer medicine.